Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent

15 Jan 2023

Abstract excerpt

Rigosertib is a small molecule in preclinical development that, due to its characteristics as a dual PLK1 and PI3K inhibitor, is particularly effective in counteracting the advance of different types of tumors. In this work, we evaluated the efficacy of Rigosertib and the expression of p53 in five different human tumor cell lines in vitro, A549 (lung adenocarcinoma), MCF-7 and MDA-MB231 (breast cancer cells),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36675237
DOI: 10.3390/ijms24021721

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Another Brick to Confirm the Efficacy of Rigosertib as Anticancer AgentPMID 36675237Read ↗

Anticancer effects of ginsenoside Rk3 on non-small cell lung cancer cells: in vitro and in vivoSemantic proximity Read ↗

Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)Semantic proximity Read ↗

Antineoplastic Effects of Erufosine on Small and Non-Small Lung Cancer Cells Through Induction of Apoptosis and Cell Cycle ArrestSemantic proximity Read ↗

p53-independent structure-activity relationships of 3-ring mesogenic compounds’ activity as cytotoxic effects against human non-small cell lung cancer linesSemantic proximity Read ↗

Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.Semantic proximity Read ↗

Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21<sup>WAF1/CIP1</sup> and p27<sup>KIP1 </sup>in Cancer CellsSemantic proximity Read ↗

Rigosertib induces cell death of a myelodysplastic syndrome‐derived cell line by <scp>DNA</scp> damage‐induced G2/M arrestSemantic proximity Read ↗

The Cell Cycle as a Target for Cancer Therapy: Basic and Clinical Findings with the Small Molecule Inhibitors Flavopiridol and UCN-01Semantic proximity Read ↗

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphomaSemantic proximity Read ↗

The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.Semantic proximity Read ↗

Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell linesSemantic proximity Read ↗

Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.